Clinical trial · Interventional
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma
NCT01212276CI-TRIAL-00015092terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor terminated protocol
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MORAb-028 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Cohort 1
- description
- MORAb-028 0.1 mg/kg intravenous
- interventionNames
- Drug: MORAb-028
- type
- EXPERIMENTAL
- label
- Cohort 2
- description
- MORAb-028 0.2 mg/kg intravenous
- interventionNames
- Drug: MORAb-028
- type
- EXPERIMENTAL
- label
- Cohort 3
- description
- MORAb-028 0.5 mg/kg intravenous
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Measurable metastatic melanoma that has failed standard therapy * Males and females greater than or equal to 18 years of age * Life expectancy of greater than or equal to 3 months Exclusion Criteria: * Significant cardiovascular impairment * Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results * Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028
References
Publications (0)
Data not yet available
No reference posted for this study.